Trial Profile
A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Rosuvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ACTE
- Sponsors Merck & Co; Merck Sharp & Dohme
- 17 May 2011 Results published in the American Journal of Cardiology.
- 19 May 2010 Actual patient number (440) added as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.